HB 2223

Kansas House bill in Session 2025-2026.

Status: enacted. Latest action: March 13, 2026.

HB2223 - Modifying certain provisions of the optometry law relating to scope of practice, definitions and credentialing requirements.

Bill ID KS-2025-2026-HB-2223
Session 2025-2026
Status enacted
Committee Public Health and Welfare
House enacted 2026-03-13
Summary

Modifying certain provisions of the optometry law relating to scope of practice, definitions and credentialing requirements.

Sponsor
House Committee on Health and Human Services
Official Source Back to Bills
Actions Timeline
Date Event Detail
2025-02-03 Introduced Bill introduced
2026-03-13 Status enacted
2026-03-13 Latest Action Approved by Governor on 03-12-2026
More Bills From This Sponsor
HB 2365
HB2365 - Adding and removing certain substances in schedules I, III and IV of the uniform controlled substances act and making conforming changes to the criminal code definition of fentanyl-related controlled substances.
enacted • House
HB 2170
HB2170 - Designating the first full week of February as Kansas burn awareness week.
in_committee • House
HB 2763
HB2763 - Requiring school districts to provide elementary students with a certain amount of daily recess, prohibiting limiting or withholding recess for disciplinary reasons, requiring a Kansas state fitness test and designating required recess time as part of the school term.
vetoed • House
HB 2676
HB2676 - Permitting a pharmacist to initiate therapy for certain conditions consistent with the pharmacist's education, training and experience, adding pharmacists who initiate such therapy to the healthcare stabilization fund and allowing a pharmacist to dispense a one-time emergency refill of a noncontrolled prescription drug for up to a 90-day supply when no refills remain.
in_committee • House
HB 2587
HB2587 - Authorizing a licensed private psychiatric hospital to maintain a stock supply of emergency medication kits for pharmaceutical emergencies.
vetoed • House
HB 2364
HB2364 - Prohibiting certain health insurers from requiring cost-sharing for nonopioid prescription drugs or providing less favorable coverage for such drug than that for opioid or narcotic prescription drugs for the treatment of pain.
in_committee • House